Cystic-fibrosis-related diabetes: time for oral drugs?

Affiliations

Comment

Antoinette Moran. Lancet Diabetes Endocrinol. 2018 Feb.

. 2018 Feb;6(2):85-87.

doi: 10.1016/S2213-8587(17)30407-2. Epub 2017 Nov 30.

¹ Department of Pediatrics, Division of Pediatric Endocrinology, University of Minnesota, Minneapolis, MN 55454, USA. Electronic address: moran001@umn.edu.

No abstract available

Comment on

Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.
Ballmann M, Hubert D, Assael BM, Staab D, Hebestreit A, Naehrlich L, Nickolay T, Prinz N, Holl RW; CFRD Study Group. Ballmann M, et al. Lancet Diabetes Endocrinol. 2018 Feb;6(2):114-121. doi: 10.1016/S2213-8587(17)30400-X. Epub 2017 Dec 5. Lancet Diabetes Endocrinol. 2018. PMID: 29199116 Clinical Trial.